Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
25.82
-0.65 (-2.46%)
At close: Apr 28, 2026, 4:00 PM EDT
25.95
+0.13 (0.50%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Maze Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Maze Therapeutics stock have an average target of 68.25, with a low estimate of 46 and a high estimate of 110. The average target predicts an increase of 164.33% from the current stock price of 25.82.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Maze Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $68 → $64 | Strong Buy | Maintains | $68 → $64 | +147.87% | Apr 14, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $52 → $58 | Buy | Maintains | $52 → $58 | +124.63% | Mar 31, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +78.16% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $110 | Strong Buy | Maintains | $60 → $110 | +326.03% | Mar 25, 2026 |
| Truist Securities | Truist Securities | Strong Buy Initiates $68 | Strong Buy | Initiates | $68 | +163.36% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
11.66M
Revenue Next Year
5.44M
from 11.66M
Decreased by -53.39%
EPS This Year
-2.87
from -3.05
EPS Next Year
-3.24
from -2.87
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 21.0M | 22.1M | ||||||
| Avg | 11.7M | 5.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 89.1% | ||||||
| Avg | - | -53.4% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.51 | -2.90 | ||||||
| Avg | -2.87 | -3.24 | ||||||
| Low | -3.30 | -3.64 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.